2 × 2 factorial design analysis of treatment results of the NHL-B1 trial
Results . | CHOP-14/21, % . | CHOEP-14/21, % . | CHO(E)P-21, % . | CHO(E)P-14, % . |
|---|---|---|---|---|
| Complete remission | 79.4 (74.7;83.4) | 87.6 (83.7;90.8) | 82.5 (78.2;86.3) | 84.6 (80.3;88.2) |
| Partial remission | 4.9 (2.9;7.7) | 3.0 (1.5;5.4) | 3.3 (1.7;5.7) | 4.6 (2.6;7.3) |
| Stable disease | 2.0 (0.8;4.1) | 0.9 (0.2;2.4) | 1.4 (0.4;3.2) | 1.5 (0.5;3.3) |
| Progressive disease | 8.0 (5.4;11.4) | 5.2 (3.2;8.1) | 8.6 (5.9;12.0) | 4.6 (2.6;7.3) |
| Therapy-associated deaths | 0.0 (0.0;1.0) | 0.8 (0.2;2.4) | 0.3 (0.0;1.5) | 0.6 (0.1;2.0) |
| Unknown | 0.3 (0.0;1.6) | 0.6 (0.1;2.0) | 0.3 (0.0;1.5) | 0.6 (0.1;2.0) |
| Additional therapy* | 5.5 (3.3;8.4) | 1.9 (0.8;3.9) | 3.6 (1.9;6.1) | 3.7 (2.0;6.3) |
| 5-y EFS† | 57.6 (52.1;63.2) | 69.2 (64.1;74.3) | 62.1 (56.8;67.4) | 65.2 (59.8;70.6) |
| 5-y overall survival† | 79.9 (75.4;84.4) | 84.1 (80.0;88.2) | 79.2 (74.8;83.7) | 85.0 (81.0;89.0) |
Results . | CHOP-14/21, % . | CHOEP-14/21, % . | CHO(E)P-21, % . | CHO(E)P-14, % . |
|---|---|---|---|---|
| Complete remission | 79.4 (74.7;83.4) | 87.6 (83.7;90.8) | 82.5 (78.2;86.3) | 84.6 (80.3;88.2) |
| Partial remission | 4.9 (2.9;7.7) | 3.0 (1.5;5.4) | 3.3 (1.7;5.7) | 4.6 (2.6;7.3) |
| Stable disease | 2.0 (0.8;4.1) | 0.9 (0.2;2.4) | 1.4 (0.4;3.2) | 1.5 (0.5;3.3) |
| Progressive disease | 8.0 (5.4;11.4) | 5.2 (3.2;8.1) | 8.6 (5.9;12.0) | 4.6 (2.6;7.3) |
| Therapy-associated deaths | 0.0 (0.0;1.0) | 0.8 (0.2;2.4) | 0.3 (0.0;1.5) | 0.6 (0.1;2.0) |
| Unknown | 0.3 (0.0;1.6) | 0.6 (0.1;2.0) | 0.3 (0.0;1.5) | 0.6 (0.1;2.0) |
| Additional therapy* | 5.5 (3.3;8.4) | 1.9 (0.8;3.9) | 3.6 (1.9;6.1) | 3.7 (2.0;6.3) |
| 5-y EFS† | 57.6 (52.1;63.2) | 69.2 (64.1;74.3) | 62.1 (56.8;67.4) | 65.2 (59.8;70.6) |
| 5-y overall survival† | 79.9 (75.4;84.4) | 84.1 (80.0;88.2) | 79.2 (74.8;83.7) | 85.0 (81.0;89.0) |
Table shows CHOP-14/21 versus CHOEP-14/21 and 3-weekly CHO(E)P-21 versus 2-weekly CHO(E)P-14. 95% Cls are shown in parentheses. Patient populations are as follows: CHOP-14/21, n = 348; CHOEP-14/21, n = 362; CHO(E)P-21, n = 361; and CHO(E)P-14, n = 349.
Radiotherapy in the absence of bulky disease, more than 6 cycles of chemotherapy, or alternative treatment.
Estimated after a median time of observation of 58 months.